Compare PBHC & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PBHC | LUNG |
|---|---|---|
| Founded | 1859 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Industrial Specialties |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 108.9M | 97.1M |
| IPO Year | 2014 | 2020 |
| Metric | PBHC | LUNG |
|---|---|---|
| Price | $16.76 | $1.86 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $3.40 |
| AVG Volume (30 Days) | 1.2K | ★ 238.8K |
| Earning Date | 11-02-2026 | 10-27-2026 |
| Dividend Yield | ★ 2.32% | N/A |
| EPS Growth | ★ 46.25 | 7.64 |
| EPS | ★ 0.47 | N/A |
| Revenue | N/A | ★ $90,497,000.00 |
| Revenue This Year | N/A | $0.06 |
| Revenue Next Year | N/A | $8.58 |
| P/E Ratio | $36.68 | ★ N/A |
| Revenue Growth | N/A | ★ 8.01 |
| 52 Week Low | $12.06 | $1.13 |
| 52 Week High | $18.30 | $2.89 |
| Indicator | PBHC | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 48.08 | 47.53 |
| Support Level | $16.71 | $1.70 |
| Resistance Level | $17.01 | $2.12 |
| Average True Range (ATR) | 0.14 | 0.11 |
| MACD | -0.08 | 0.01 |
| Stochastic Oscillator | 7.50 | 58.14 |
Pathfinder Bancorp Inc is a holding company for Pathfinder Bank. The Pathfinder Bank is a commercial bank engaged in attracting deposits from the general public and investing such deposits, together with other sources of funds, in loans secured by residential real estate, commercial real estate, small business loans, and consumer loans. The bank invests a portion of its assets in debt securities issued by the United States Government and its agencies and sponsored enterprises, state and municipal obligations, corporate debt securities, mutual funds, and equity securities. The principal source of income is interest on loans and investment securities.
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.